Veterinary Vaccines Market, By Vaccine Type (Livestock Vaccine, Companion Animal Vaccine), By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Other), By Region, Competition 2020-2030F

Market Overview

Global Veterinary Vaccines Market has valued at USD 8.44 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.28% through 2030F. ​The global veterinary vaccines market is a vital segment of the veterinary healthcare industry, focusing on the development, production, and distribution of vaccines to prevent and control diseases in animals, including both companion animals and livestock. These vaccines are essential for maintaining animal health, ensuring food security, and preventing the transmission of zoonotic diseases—those that can transfer between animals and humans.​

A significant driver of market growth is the increasing global population of companion animals, such as dogs, cats, and horses. Pet owners are increasingly prioritizing the health and longevity of their animals, leading to a higher willingness to invest in healthcare services, including vaccinations. This trend is particularly evident in developed regions like North America and Europe, where pet ownership rates are high. For instance, in the United States, approximately 66% of households owned a pet, reflecting a steady increase in pet ownership. ​Emerging economies are also witnessing a surge in pet adoption, driven by urbanization and rising disposable incomes. Countries such as India and China have experienced significant growth in their companion animal populations, which in turn fuels the demand for veterinary vaccines. This expansion is supported by increased awareness of animal health and the benefits of preventive care. Technological advancements in vaccine development, including the adoption of recombinant and DNA-based vaccines, have enhanced the efficacy and safety profiles of veterinary vaccines. These innovations have led to higher adoption rates among veterinarians and animal owners, further propelling market growth. ​Government initiatives aimed at controlling and eradicating animal diseases, particularly in developing regions, have created significant opportunities for market players. Increased funding for research and development in veterinary medicine, coupled with the growing trend toward organic and antibiotic-free animal products, has boosted the demand for vaccines as a preventive measure against infectious diseases.

Key Market Drivers

Rising Incidence of Animal Diseases

The global veterinary vaccine market is significantly influenced by the increasing incidence of infectious diseases among animals. These diseases can affect various species, including livestock (cattle, poultry, swine) and companion animals (dogs, cats). Examples of such diseases include foot-and-mouth disease, avian influenza, bovine respiratory disease, and canine parvovirus. For instance, between January and June 2024, 55 countries reported over 3,800 wildlife disease outbreaks, affecting 151 species, with 10% at risk of extinction. Highly pathogenic avian influenza (HPAI) and African swine fever (ASF) accounted for most cases, significantly impacting wildlife and domestic animals. Protecting wildlife health is crucial for safeguarding food security, biodiversity, and human well-being. Animal diseases can have severe economic consequences. Outbreaks can lead to reduced livestock productivity, increased mortality rates, and trade restrictions. For farmers and livestock producers, this translates into substantial financial losses. To mitigate these impacts, vaccines are developed and administered to prevent the occurrence and spread of these diseases. The concept of One Health emphasizes the interconnectedness of human, animal, and environmental health. Preventing animal diseases is not only essential for the well-being of animals but also for public health. Diseases that can jump from animals to humans (zoonoses) highlight the importance of veterinary vaccines in safeguarding both animal and human populations.

Growing Awareness of Animal Welfare

There is a notable shift in public attitudes toward animal welfare, driven by increased awareness and concern for the well-being of animals. Pet owners are more willing to invest in healthcare for their pets, including vaccinations, to ensure their health and longevity. In the livestock industry, there is a growing recognition that healthy and well-cared-for animals lead to higher productivity and food safety. Consumers are increasingly demanding ethically and sustainably sourced animal products, which incentivizes livestock producers to prioritize animal health and welfare. Regulatory bodies and animal welfare organizations have introduced guidelines and certification programs that encourage the humane treatment of animals. These guidelines often include recommendations for disease prevention through vaccination. In November 2024, the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) issued its first certification for a vaccine platform technology master file (vPTMF). This certification aims to expedite the development and approval of new veterinary vaccines in the EU. The certified Innovax vPTMF, developed by Intervet International B.V., utilizes a turkey herpesvirus vector backbone already employed in several authorized vaccines for chickens. This platform can be rapidly adapted for emerging diseases, enhancing preparedness for animal and public health threats.

Technological Advancements in Vaccine Development

Advances in biotechnology and genomics have revolutionized vaccine development. Researchers can now identify antigens more precisely and design vaccines tailored to specific pathogens. This has led to the development of subunit vaccines and recombinant vaccines with improved safety profiles. Technological innovations have also improved vaccine delivery methods. Traditional injectable vaccines are being supplemented with alternatives such as oral vaccines and intranasal vaccines, which can be administered more easily and with reduced stress for animals. Modern vaccine development techniques enable the creation of vaccines that are both highly efficacious and safe. This instills confidence in veterinarians, pet owners, and livestock producers, encouraging greater vaccine adoption.

Government Initiatives and Regulations:

Many governments around the world have implemented mandatory vaccination programs for specific diseases in animals. For example, bovine brucellosis vaccination is required in cattle in some regions to prevent the disease's spread. Vaccination of livestock is often tied to food safety and international trade regulations. Governments may require certain vaccinations to ensure the safety of animal-derived products for human consumption and to facilitate international trade. Governments and public health agencies often fund research and development efforts related to animal vaccines. This financial support can lead to the discovery and development of new and improved vaccines for various animal species.

Download Free Sample Report

Key Market Challenges

Regulatory Hurdles and Approval Processes

Complex Regulatory Landscape: Developing and marketing veterinary vaccines involves navigating a complex regulatory landscape. Different countries and regions have their own regulatory agencies and requirements for vaccine approval. Complying with these regulations can be time-consuming and costly for vaccine manufacturers.

Stringent Safety and Efficacy Standards: Regulatory agencies impose stringent safety and efficacy standards on veterinary vaccines to ensure the well-being of animals and prevent potential risks to human health. Meeting these standards often requires extensive preclinical and clinical testing, which can be expensive and time intensive.

Vaccine Registration Delays: Delays in the registration and approval of veterinary vaccines can significantly slow down market growth. Manufacturers must invest in research, development, and clinical trials, and any delays in the approval process can hinder their ability to bring vaccines to market in a timely manner.

Market Fragmentation and Competitive Challenges

The global veterinary vaccine market is fragmented, with many manufacturers, including both multinational pharmaceutical companies and smaller, specialized firms. This fragmentation can lead to intense competition and pricing pressures. Customers, such as farmers and pet owners, are often price-sensitive when it comes to veterinary vaccines. This can make it challenging for vaccine manufacturers to maintain profitability, particularly when competing with lower-cost alternatives. Expanding into emerging markets can be difficult due to variations in regulatory requirements, distribution channels, and local preferences. Manufacturers must adapt their strategies to suit each market, which can be resource intensive.

Emerging Diseases and Antigenic Variability

The emergence of new and unpredictable animal diseases can pose significant challenges to the veterinary vaccine market. Developing vaccines for these diseases often requires extensive research and development, and the timeline to market may not align with the urgency of addressing disease outbreaks. Some pathogens, like influenza viruses, exhibit antigenic variability, meaning they can mutate over time. This variability can render existing vaccines less effective, necessitating frequent updates and reformulations. This poses technical and logistical challenges for vaccine manufacturers to stay ahead of evolving pathogens. Some diseases, particularly zoonotic diseases that can be transmitted between animals and humans, may have reservoir hosts in wildlife. Controlling these diseases through vaccination can be challenging due to the difficulty of vaccinating wild animals.

Key Market Trends

Increasing Focus on Preventive Healthcare:

One prominent trend in the global veterinary vaccine market is the increasing emphasis on preventive healthcare for animals. Pet owners and livestock producers are recognizing the importance of vaccination as a proactive measure to protect animals from infectious diseases. Preventive healthcare not only improves the overall well-being of animals but also reduces the economic burden associated with treating sick animals.

This trend is particularly evident in the companion animal sector, where pet owners are more willing to invest in routine vaccinations to ensure the health and longevity of their pets. In the livestock industry, preventive vaccination is becoming standard practice to maintain herd health and productivity.

Advancements in Vaccine Technology:

Advances in vaccine technology are driving innovation in the veterinary vaccine market. These advancements encompass various aspects of vaccine development, production, and administration: Researchers are exploring new vaccine platforms, such as DNA vaccines, recombinant vaccines, and virus-like particle vaccines. These platforms offer improved safety, efficacy, and ease of production. Improved adjuvants and delivery systems are enhancing vaccine effectiveness and reducing the need for booster shots. These innovations are making vaccines more convenient for both pet owners and livestock producers. Advances in genomics and antigen discovery are enabling the development of targeted and customized vaccines that provide better protection against specific pathogens. This trend is particularly relevant for addressing emerging and evolving diseases.

Globalization and Market Expansion:

The global veterinary vaccine market is experiencing significant expansion, driven by globalization and increased trade in animal products. Several related trends contribute to this growth:

Emerging markets in Asia, Latin America, and Africa are witnessing a rise in demand for veterinary vaccines. As these regions undergo economic development and urbanization, the demand for animal protein and pet ownership is increasing, driving the need for vaccines. The international trade of animals and animal products necessitates compliance with international health and safety standards. This, in turn, boosts the demand for vaccines to ensure the health and safety of animals in transit. Vaccine manufacturers are forming collaborations and partnerships to expand their global presence and access new markets. This includes joint ventures, licensing agreements, and distribution partnerships.

Segmental Insights

Vaccine Type Insights

Based on the category of Vaccine Type, the livestock vaccine segment emerged as the dominant player in the global market for Veterinary Vaccines in 2024. The dominance of the livestock vaccine segment in the global veterinary vaccine market can be attributed to several factors related to the types of vaccines used in the livestock industry. Livestock vaccines are specifically designed to address the health and disease prevention needs of various farm animals, including cattle, swine, poultry, sheep, and goats.

The Livestock vaccines encompass a wide range of vaccine types tailored to different livestock species and specific diseases. This diversity includes vaccines for diseases like foot-and-mouth disease, bovine respiratory disease, avian influenza, porcine circovirus-associated disease, and many others.

The livestock industry places a strong emphasis on preventive healthcare to maintain herd health and productivity. Vaccination is a cornerstone of this approach. Livestock vaccines are formulated to protect animals from diseases that can cause substantial economic losses through reduced production, increased mortality, and trade restrictions. The global livestock population is immense, with billions of animals raised for meat, milk, and other products. For example, there are over 1.5 billion cattle and nearly 25 billion chickens globally. Such large populations create a significant demand for vaccines to protect these animals from infectious diseases. Livestock farming is a vital component of the global agriculture industry, contributing to food security and economic stability in many countries. Consequently, the economic impact of disease outbreaks in livestock can be substantial, driving the need for vaccination. Livestock can be vulnerable to a range of infectious diseases, some of which are highly contagious and can spread rapidly within herds or flocks. Controlling and preventing these diseases often requires a multifaceted approach, with vaccination being a critical component. Some livestock diseases can have zoonotic potential, meaning they can be transmitted from animals to humans. Preventing these diseases through vaccination is not only essential for animal health but also for public health. These factors are expected to drive the growth of this segment.

Technology Insights

The live attenuated vaccines segment is projected to experience rapid growth during the forecast period. Live attenuated vaccines are a category of vaccines that contain weakened or modified forms of the pathogen they target. Live attenuated vaccines often provide a stronger and more sustained immune response compared to other types of vaccines. This is because they closely mimic natural infections, stimulating both humoral (antibody) and cellular immunity.

In many cases, live attenuated vaccines require fewer doses to confer long-lasting immunity. This is particularly advantageous in veterinary settings where administering multiple doses can be challenging, especially for farm animals. Live attenuated vaccines have played a crucial role in eradicating or controlling several devastating animal diseases. For example, the use of live attenuated vaccines has been instrumental in controlling diseases like rinderpest in cattle and pseudorabies in pigs. In the event of disease outbreaks, live attenuated vaccines can be rapidly deployed to control the spread of the disease and protect vulnerable populations of animals. Live attenuated vaccines often provide cross-protection against multiple strains or variants of a pathogen. This is particularly valuable when dealing with pathogens that exhibit antigenic variation. Live attenuated vaccines can be used to protect against a wide range of viral and bacterial diseases, making them versatile tools for veterinarians and livestock producers. These factors collectively contribute to the growth of this segment.

Regional Insights

North America emerged as the dominant player in the global Veterinary Vaccines market in 2024, holding the largest market share in terms of value. The United States has a significant population of pets, including dogs, cats, and horses, leading to a substantial demand for companion animal vaccines. North America boasts a well-developed livestock industry, with high-quality beef and dairy production. This has led to a substantial need for livestock vaccines to maintain herd health and productivity. The region is home to leading veterinary research institutions and vaccine manufacturers, driving innovation and the development of new vaccine technologies.

Download Free Sample Report

Recent Developments

• On July 25, 2023, Zoetis announced that it has entered into a strategic partnership with Boehringer Ingelheim to develop and commercialize new vaccines for livestock. The partnership will see Zoetis and Boehringer Ingelheim work together to develop new vaccines that address the needs of livestock producers around the world.
• On August 29, 2023, Merck & Co. Inc. announced that the European Commission has approved Keytruda® (pembrolizumab) as first-line treatment for patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). Keytruda is a checkpoint inhibitor that works by blocking the PD-1 protein, which helps cancer cells evade the immune system.   
• On July 27, 2023, Virbac announced that it has received approval from the European Medicines Agency (EMA) for its new drug, Vectra3D, for the treatment of heartworm disease in dogs. Vectra3D is a single-dose injectable drug that is the first and only drug that can provide long-lasting protection against heartworm disease in dogs.
• On July 20, 2023, Hester Biosciences Limited announced that it has entered into a strategic partnership with Novapharma to develop and commercialize vaccines for poultry and other animals in Egypt. The partnership will see Hester Biosciences and Novapharma work together to develop and commercialize vaccines that address the needs of the Egyptian poultry and animal health markets.

Key Market Players

• Zoetis Inc.
• Merck & Co. Inc.
• Virbac SA
• Hester Biosciences Limited
• Elanco Animal Health
• Boehringer Ingelheim International GmbH
• Ceva Sante Animale
• Phibro Animal Health Corporation
• HIPRA

Report Scope:

In this report, the Global Veterinary Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Veterinary Vaccines Market, By Vaccine Type:

o   Livestock Vaccine

o   Companion Animal Vaccine

• Veterinary Vaccines Market, By Technology:

o   Live Attenuated Vaccines

o   Inactivated Vaccines

o   Toxoid Vaccines

o   Recombinant Vaccines

o   Other

• Veterinary Vaccines Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Vaccines Market.

Available Customizations:

Global Veterinary Vaccines market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).